FDA Officially Classifies Menopause Tests as Safe Class II Devices
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting menopause test systems into a special safety group called Class II to make sure they work well and are safe. This change helps companies bring better menopause tests to patients faster and with fewer hoops to jump through. If you make or use these tests, expect smoother rules soon, helping everyone get reliable results without extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Menopause Tests Classified as Class II
The FDA has officially classified menopause test systems as class II (special controls). This classification is meant to provide a reasonable assurance of safety and effectiveness and to enhance patients' access to beneficial innovative devices by reducing regulatory burdens. You may see more reliable menopause test options because the rule makes safety and performance rules part of the official classification.
Firms Face Lower Regulatory Burden
The FDA says classifying the menopause test system into class II will reduce regulatory burdens for companies that make these tests. That can help firms bring menopause test devices to market faster and with fewer regulatory hoops to jump through. If you make or sell these tests, you may have smoother rules to follow when seeking approval.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in